U.S. Cancer Centers Face Critical Drug Shortages
美國癌症中心面臨嚴重的藥物短缺
更新於: 2026年9月23日 上午01:16
As of September 2026, U.S. cancer centers are grappling with an unprecedented crisis: a universal shortage of essential anticancer medications.
截至2026年9月，美國的癌症中心正面臨一場前所未有的危機：必需抗癌藥物出現了普遍性的短缺。
According to a recent survey by the National Comprehensive Cancer Network, every single responding cancer center is currently facing a deficit of at least one critical drug.
根據國家癌症綜合網絡近期的一項調查，每一家受訪的癌症中心目前都面臨至少一種關鍵藥物的短缺。
The impact on patient care is severe, with nearly 70% of hospitals forced to ration medications, lower doses, or delay treatment schedules.
這對病患照護造成嚴重影響，近70%的醫院被迫採取配給藥物、降低劑量或延後治療時程等措施。
Furthermore, the administrative burden of seeking new insurance authorizations for modified treatment plans is causing dangerous delays.
此外，因修改治療計畫而須尋求新的保險授權，其行政負擔也導致了危險的延誤。
The root of the issue lies in a fragile pharmaceutical supply chain.
問題的根源在於脆弱的藥品供應鏈。
While hospitals are working to manage these gaps internally, experts argue that until structural policy reforms address manufacturing incentives and supply chain vulnerabilities, patients remain at risk of compromised care and higher rates of disease progression.
儘管醫院正努力在內部控管這些缺口，但專家認為，若結構性的政策改革無法解決製造誘因與供應鏈脆弱性，患者仍將面臨照護品質下降與疾病惡化率提高的風險。
